Efficacy of a Novel Palivizumab Prophylaxis Protocol for Respiratory Syncytial Virus Infection in Congenital Heart Disease: A Multicenter Study
- 1 April 2018
- journal article
- research article
- Published by Elsevier in The Journal of Pediatrics
- Vol. 195, 108-114.e1
Abstract
No abstract availableKeywords
Funding Information
- Taiwan Society of Pediatric Cardiology (TSPC-201401)
This publication has 24 references indexed in Scilit:
- Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2012
- Meta‐analysis of passive immunoprophylaxis in paediatric patients at risk of severe RSV infectionActa Paediatrica, 2010
- Cost Effectiveness of Respiratory Syncytial Virus ProphylaxisPharmacoEconomics, 2010
- Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus InfectionsPediatrics, 2009
- Role of Pulse Oximetry in Examining Newborns for Congenital Heart Disease: A Scientific Statement from the AHA and AAPPediatrics, 2009
- Annual Variation in Respiratory Syncytial Virus Season and Decisions Regarding Immunoprophylaxis With PalivizumabPediatrics, 2004
- Safety and Pharmacokinetics of Palivizumab Therapy in Children Hospitalized with Respiratory Syncytial Virus InfectionThe Pediatric Infectious Disease Journal, 2004
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- Respiratory syncytial virus epidemics: the ups and downs of a seasonal virusThe Pediatric Infectious Disease Journal, 2003
- Circulation Patterns of Group A and B Human Respiratory Syncytial Virus Genotypes in 5 Communities in North AmericaThe Journal of Infectious Diseases, 2000